Drug Discovery World
AUGUST 22, 2023
Claire D’Abreau-Hayling, Chief Scientific Officer at Sandoz, examines how generic products can relieve industry pressure and improve access to essential medicines. Off-patent medicines today account for about 80% of global prescriptions at an estimated 20% of the total cost. Complex generics comprise a diverse range of products.
Pharmaceutical Technology
APRIL 13, 2023
The company is aiming to refocus its efforts on its core therapeutic areas and current late-stage programmes such as the oral TYK2 inhibitor TAK-279, which is under development for several autoimmune disorders.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Camargo
NOVEMBER 11, 2020
Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely. In October, the U.S.
Drug Discovery World
SEPTEMBER 28, 2022
Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace. According to Hampleton Patners’ latest Healthtech M&A market report2, digital health companies raised a total of $57.2
Drug Discovery World
NOVEMBER 16, 2022
DDW Editor Reece Armstrong learns about Molecular Devices’ Organoid Innovation Centre (OIC) and how the company is aiming to advance research into 3D biology and organoids. . Therefore, while researchers can understand just how a drug molecule impacts a cell, they can’t be sure that it will perform the same when used in-vivo. .
Drug Discovery World
OCTOBER 4, 2022
The company’s candidate screening approach recapitulates aspects of tau oligomer formation in neurodegenerative diseases and enables the identification of novel therapeutic approaches. Several of the large pharma companies have recently re-entered the dementia field. With its recent award of $3.35 Overcoming sector challenges
Pharmaceutical Technology
MAY 24, 2023
Every major pharma company is now involved in CGT development which has resulted in the approval of 28 therapies by the FDA thereby making CGT no longer a niche category of therapies. Allogeneic therapies begin with healthy donor samples to develop the eventual therapeutic product which can be administered to multiple patients.
Expert insights. Personalized for you.
52 
Let's personalize your content